SG11201407924RA - METHOD OF TREATING <i>SCEDOSPORIUM SPP</i>. INFECTION - Google Patents

METHOD OF TREATING <i>SCEDOSPORIUM SPP</i>. INFECTION

Info

Publication number
SG11201407924RA
SG11201407924RA SG11201407924RA SG11201407924RA SG11201407924RA SG 11201407924R A SG11201407924R A SG 11201407924RA SG 11201407924R A SG11201407924R A SG 11201407924RA SG 11201407924R A SG11201407924R A SG 11201407924RA SG 11201407924R A SG11201407924R A SG 11201407924RA
Authority
SG
Singapore
Prior art keywords
international
infection
new south
south wales
scedosporium spp
Prior art date
Application number
SG11201407924RA
Other languages
English (en)
Inventor
Julie Phillips
Tania Sorrell
Sharon Chen
Original Assignee
Biodiem Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012902243A external-priority patent/AU2012902243A0/en
Application filed by Biodiem Ltd filed Critical Biodiem Ltd
Publication of SG11201407924RA publication Critical patent/SG11201407924RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201407924RA 2012-05-30 2013-05-13 METHOD OF TREATING <i>SCEDOSPORIUM SPP</i>. INFECTION SG11201407924RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2012902243A AU2012902243A0 (en) 2012-05-30 Method of treating Seedosporium spp. infection
PCT/AU2013/000487 WO2013177608A1 (en) 2012-05-30 2013-05-13 Method of treating scedosporium spp. infection

Publications (1)

Publication Number Publication Date
SG11201407924RA true SG11201407924RA (en) 2014-12-30

Family

ID=49672167

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407924RA SG11201407924RA (en) 2012-05-30 2013-05-13 METHOD OF TREATING <i>SCEDOSPORIUM SPP</i>. INFECTION

Country Status (9)

Country Link
US (1) US9867802B2 (enExample)
EP (1) EP2854799B1 (enExample)
JP (1) JP2015518007A (enExample)
CN (1) CN104519882A (enExample)
AU (2) AU2013204604B2 (enExample)
CA (1) CA2874881A1 (enExample)
SG (1) SG11201407924RA (enExample)
WO (1) WO2013177608A1 (enExample)
ZA (1) ZA201408975B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019023741A1 (en) * 2017-08-01 2019-02-07 Opal Biosciences Limited TREATMENT OF STAPHYLOCOCCUS AND ENTEROCOCCUS INFECTIONS USING SUBSTITUTED NITROSTYRENE COMPOUNDS
WO2020097398A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
CA3181537A1 (en) 2020-05-06 2021-11-11 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
WO2022140527A1 (en) 2020-12-23 2022-06-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
TW202325289A (zh) 2021-11-09 2023-07-01 美商雅捷可斯治療公司 Ｊａｋ２抑制劑之形式及組合物
TW202334139A (zh) 2021-11-09 2023-09-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳氧基苯并咪唑及氮雜苯并咪唑

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985761A (en) * 1974-10-24 1976-10-12 Sarabhai Research Centre Nitrothiazolyl derivatives of nitrostyrene
JPS585902B2 (ja) * 1978-09-01 1983-02-02 株式会社大塚製薬工場 β↓−ニトロスチレン誘導体
RU2259825C9 (ru) * 2001-06-18 2006-04-10 БиоДием Лимитед Вещества, проявляющие антимикробную, антигрибковую, антипротозойную активности
US20080220103A1 (en) * 2005-10-24 2008-09-11 Jay Birnbaum Method for treating/controlling/killing fungi and bacteria on living animals
JP2009512729A (ja) * 2005-10-24 2009-03-26 スタヴァル ファーマ リミテッド 菌類及び細菌を処理、抑制、殺滅する方法
WO2008061308A1 (en) * 2006-11-22 2008-05-29 Biodiem Ltd Protein tyrosine phosphatase modulators
AU2009240389A1 (en) * 2008-04-25 2009-10-29 Nanobio Corporation Nanoemulsions for treating fungal, yeast and mold infections
UA107963C2 (xx) * 2010-06-07 2015-03-10 Janssen Pharmaceutica Nv ПРОТИГРИБКОВІ ПОХІДНІ 5,6-ДИГІДРО-4-$(ДИФТОРЕТИЛ)ФЕНІЛ]-4H-ПІРОЛО$1,2-a]$1,4]БЕНЗОДІАЗЕПІНУ І 4-(ДИФТОРЕТИЛ)ФЕНІЛ-6H-ПІРОЛО$1,2-a]$1,4]БЕНЗОДІАЗЕПІНУ

Also Published As

Publication number Publication date
US20150126436A1 (en) 2015-05-07
AU2013204604B2 (en) 2016-05-19
CN104519882A (zh) 2015-04-15
ZA201408975B (en) 2016-10-26
US9867802B2 (en) 2018-01-16
EP2854799B1 (en) 2018-04-25
HK1209052A1 (en) 2016-03-24
CA2874881A1 (en) 2013-12-05
JP2015518007A (ja) 2015-06-25
AU2013270430A1 (en) 2014-12-18
EP2854799A4 (en) 2015-10-21
AU2013204604A1 (en) 2013-12-19
WO2013177608A1 (en) 2013-12-05
EP2854799A1 (en) 2015-04-08

Similar Documents

Publication Publication Date Title
SG11201407200TA (en) Liquid formulation
SG11201901747VA (en) Inhibitors of cellular metabolic processes
SG11201907650RA (en) Personal therapy and exercise monitoring and oversight devices, systems, and related methods
SG11201408133TA (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
SG11201907034PA (en) Methods of treating influenza
SG11201408094YA (en) Neprilysin inhibitors
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201407037UA (en) Catechol o-methyltransferase activity inhibiting compounds
SG11201803686UA (en) Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease
SG11201407534PA (en) New diazaspirocycloalkane and azaspirocycloalkane
SG11201406787TA (en) Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201408261UA (en) Syringe
SG11201407924RA (en) METHOD OF TREATING &lt;i&gt;SCEDOSPORIUM SPP&lt;/i&gt;. INFECTION
SG11201407867VA (en) Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201407372UA (en) Nampt inhibitors
SG11201408383SA (en) Methods of detecting diseases or conditions using circulating diseased cells
SG11201407536UA (en) Topical pharmaceutical compositions comprising terbinafine and urea
SG11201408685WA (en) Antibacterial microelement chelates and the use thereof in animal feeds
SG11201805001UA (en) Method of treating influenza a
SG11201407801VA (en) Methods for use of mixed multifunctional surfaces for reducing aggregate content in protein preparations
SG11201810974QA (en) Methods and compositions for prostate cancer diagnosis and treatment
SG11201805263TA (en) Compositions and methods for detecting and treating esophageal cancer